pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,821 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1876Endpoints1458Fierce Biotech771BioSpace762BioPharma Dive551raps249onclive165fda recalls
therapy area
allOncology12974Rare Disease3368Immunology3056Cardiology2860Hematology2314Pulmonology2256Vaccines
  • Tango combo clears Rasonque bar and Takeda's Innovent sees early returns as ESMO data leaks dampen hype
    The first day of the European Society for Medical Oncology (ESMO) congress opened in Madrid with several notable updates from the oncology field. Tango's combination therapy cleared the Rasonque r…
    Endpoints · 27d agoRegulatoryNeutral↗ source
  • Voyager Therapeutics CEO Al Sandrock to resign next year, remains on board; Insmed appoints Paul Hudson as director
    Voyager Therapeutics announced that its chief executive, Al Sandrock, will step down in the first quarter of next year. Sandrock will continue to serve on Voyager's board after his resignation, pr…
    Endpoints · 27d agoNeutral↗ source
← prev
page 23 of 153
next →
122
fda medwatch116
globenewswire health73
fda press62
1861
Psychiatry & CNS1235
Ophthalmology1140
Endocrinology & Metabolism809
Pain793
Nephrology788
  • Family reflects on extra months gained from new pancreatic cancer drug daraxonrasib
    Bobby Senaha was among the first patients to receive daraxonrasib, a new medicine aimed at extending survival for people with pancreatic cancer. The drug is described as life extending, offering p…
    STAT · 27d agoPositive↗ source
  • Lung cancer patient credits targeted therapy for 15-year survival, notes limited benefit for others
    A lung cancer patient described how a targeted drug allowed her to live for 15 years after diagnosis. She highlighted that while her own quality of life improved, many of her peers who received th…
    STAT · 27d agoNeutral↗ source
  • Drug safety group petitions FDA to block marketing of unapproved compounded peptides; bipartisan bill seeks clinical trial reforms
    A drug safety advocacy group has filed a citizen petition with the FDA, asking the agency to stop the marketing of compounded peptide products that lack approval. A bipartisan group of lawmakers h…
    raps · 27d agoRegulatoryNeutral↗ source
  • Experts urge cultural shift and standards to unlock real-world evidence potential in medtech
    At The MedTech Conference in Boston, experts highlighted the need for a cultural shift to build trust between regulators and medtech firms when using real-world evidence (RWE) for device marketing.…
    raps · 27d agoNeutral↗ source
  • ADA admits unclear policies after ejecting members, sparks boycott and journal shutdown
    The American Diabetes Association ejected five members from a scientific session in New Orleans on June 5 and later issued two explanations, an apology and a summary of its internal review. The org…
    STAT · 27d agoNegative↗ source
  • Callio Therapeutics appoints Chris Hassig as chief scientific officer, coming from Boundless Bio
    STAT+ regularly highlights personnel changes across the pharmaceutical sector. In its latest column the outlet reports a new senior appointment at Callio Therapeutics. The company has hired Chris…
    STAT · 27d agoPositive↗ source
  • States Challenge New Medicaid Work Requirements in Boston Court
    A federal judge in Boston heard arguments from about two dozen states contesting the Biden administration’s new Medicaid work-requirement rule. The states claim Health Secretary Robert F. Kennedy…
    STAT · 27d agoRegulatoryNegative↗ source
  • Opioid Overdose Deaths Have Plummeted, Experts Call for Deeper Investigation
    Recent data indicate a steep drop in opioid overdose deaths. The decline is notable compared with previous years. Three health experts argue that influences beyond medical treatment and public hea…
    STAT · 27d agoPositive↗ source
  • STAT honors late infectious disease reporter Helen Branswell on The Readout LOUD podcast
    The Readout LOUD podcast dedicated an episode to remembering Helen Branswell, a well‑known infectious disease journalist who passed away last week. Colleagues, family, and public health leaders sh…
    STAT · 27d agoNegative↗ source
  • Writer empathizes with Christina Applegate’s MS misdiagnosis, recalling her own 13-year diagnostic journey
    The author of the piece shares a personal connection to actress Christina Applegate’s recent revelation that she was told she no longer had multiple sclerosis, only to discover the news was a misdi…
    STAT · 27d agoNeutral↗ source
  • STAT reporters share reactions to new Elizabeth Holmes documentary
    STAT reporters attended the newly released documentary "You Can See Everything," which chronicles the rise and fall of Elizabeth Holmes and her company Theranos. The reporters offered a range of h…
    STAT · 27d agoNeutral↗ source
  • STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early
    In data released at ESMO, the Moderna-Merck personalized mRNA cancer vaccine reduced recurrence-free survival and the time until distant metastasis occurred.
    STAT · 27d ago↗ source
  • STAT+: Treasury proposes major restrictions to U.S. investment in Chinese biotech sector
    A new Treasury Department proposal would restrict U.S. investments in Chinese biotechs, but still allows licensing deals.
    STAT · 27d ago↗ source
  • Moderna and Merck's mRNA melanoma vaccine cuts recurrence risk by 42% in trial
    A large Phase 2 trial led by Moderna and Merck showed that their personalized mRNA vaccine, intismeran autogene, lowered the chance of melanoma returning by 42% compared with standard therapy. The…
    STAT · 28d agoPositive readoutPositive↗ source
  • Merck and Moderna’s cancer vaccine data leak precedes official Phase 3 results release
    Results from the Phase 3 trial of Moderna and Merck’s therapeutic cancer vaccine were made public on Thursday after an earlier leak of the data. The vaccine, called intismeran autogene, is being e…
    Endpoints · 28d agoNeutral↗ source
  • U.S. proposes rule tightening review of biotech licensing deals with Chinese firms
    The U.S. is preparing to issue a proposed rule that would place additional scrutiny on outbound licensing agreements between American biotech firms and Chinese companies. The measure aims to increa…
    STAT · 28d agoRegulatoryNeutral↗ source
  • FDA approves GSK hepatitis B drug; EQT to acquire Qiagen for $10.8 billion
    The U.S. Food and Drug Administration has granted approval to GlaxoSmithKline's new hepatitis B therapy, marking a regulatory milestone for the company. Private-equity firm EQT announced a definit…
    raps · 28d agoPositive↗ source
  • US Treasury drafts rules to curb American investment in Chinese biotech firms
    The Treasury Department has released draft regulations that would impose broad restrictions on U.S. companies and venture capital firms investing in or acquiring drug and biotechnology assets linke…
    Endpoints · 28d agoRegulatoryNegative↗ source
  • Pfizer and Valneva report mixed results for Lyme disease vaccine, with one analysis narrowly missing efficacy
    New data on the collaborative Lyme disease vaccine from Pfizer and Valneva were presented, showing divergent outcomes across two key analyses. One analysis met its predefined endpoints, while the o…
    Endpoints · 28d agoNegative readoutNegative↗ source
  • Roche prepares launch of breast cancer pill giredestrant amid patient anticipation
    Roche is gearing up for the launch of its new oral breast cancer therapy, giredestrant. Teresa Graham, head of Roche's pharma unit, said patients are anxiously awaiting the drug. The announcement…
    Endpoints · 28d agoPositive↗ source
  • Regulatory update: Hepatitis B hold lifted for Arbutus drug and Ultomiris receives accelerated approval
    A regulatory update notes that the FDA has removed the clinical hold on Arbutus Biopharma's hepatitis B candidate, clearing the path for the company to resume development after a prolonged review.…
    Endpoints · 28d agoRegulatoryPositive↗ source
  • AbbVie reports Phase 3 success for lutikizumab in painful skin disease, eyes FDA filing next year
    AbbVie announced positive Phase 3 trial results for its experimental IL-1α and IL-1β inhibitor lutikizumab, which is being developed to treat a debilitating skin condition. The study reported impr…
    Endpoints · 28d agoPositive readoutPositive↗ source
  • Sanofi breaks ground on new 36,000-sq-m insulin plant in Frankfurt
    Sanofi has broken ground on a new insulin manufacturing facility at its Frankfurt site, covering roughly 36,000 square meters. The plant is part of the company’s expansion in Germany and is expect…
    Endpoints · 28d agoNeutral↗ source